Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma that is believed to originate from primitive mesenchymal cells that typically differentiate into skeletal tissue. However, these tumors can also arise in other types of tissue and any anatomic area. RMS is the most common soft tissue sarcoma diagnosed in children; only 1% to 2% of these cancers are found in adults. The etiology and risk factors remain largely unknown. Most cases of rhabdomyosarcoma are sporadic; however, the disease can be associated with familial syndromes. Rhabdomyosarcoma is classified into histologic subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Embryonal is the most commonly occurring subtype and also has the best prognosis. The management approach is tailored to a patient’s risk stratification. Two systems are used to characterize risk stratification for RMS: the Clinical Group or the Stage. Each system uses different factors to categorize patients according to risk, and most authorities use both to determine the most appropriate therapeutic approach. Currently, treatment is multimodal, combining surgery, when feasible, to completely remove the primary tumor and chemotherapy to control disease spread, even if no evidence of metastasis is present on imaging because most patients have been found to have micrometastasis in studies. Radiotherapy is used to treat most high and intermediate-risk patients as well. The survival of rhabdomyosarcoma patients has improved due to interprofessional collaboration, leading to advancements in diagnosis and management approaches. This activity for healthcare professionals is designed to enhance the learner’s competence when managing rhabdomyosarcoma, equipping them with updated knowledge, skills, and strategies for timely diagnosis and effective interventions, as well as highlighting the role of interprofessional coordination of care, leading to better outcomes for patients and reduced morbidity.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/28510
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
ABOS - 1.5 Point; Credit Type(s): Accredited CME (ABOS)
ABPATH - 1.5 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.5 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.5 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.5 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.5 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABTS - 1.5 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Ambulatory/Outpatient, Complex General Surgical Oncology, Critical Care Medicine, General Operative Anesthesia, General Orthopaedics, General Pediatrics, General Surgery, Hospice and Palliative Medicine, Hospital Medicine, Internal Medicine, Medical Oncology, Musculoskeletal Oncology, Non-Thoracic Surgery, Orthopaedic Sports Medicine, Pediatric Anesthesia, Pediatric Critical Care Medicine, Pediatric Emergency Medicine, Pediatric Hematology-Oncology, Pediatric Orthopaedic Surgery, Pediatric Pathology, Pediatric Surgery, Soft Tissue & Bone, Surgical Critical Care